| Literature DB >> 33865691 |
Elizabeth Needham Waddell1, Sandra A Springer2, Lisa A Marsch2, David Farabee3, Robert P Schwartz4, Amesika Nyaku5, Rusty Reeves6, Keith Goldfeld3, Ryan D McDonald3, Mia Malone4, Anna Cheng4, Elizabeth C Saunders2, Laura Monico4, Jan Gryczynski4, Kathleen Bell2, Kasey Harding7, Sandra Violette8, Thomas Groblewski9, Wendy Martin10, Kasey Talon10, Nicole Beckwith10, Andrew Suchocki11, Randy Torralva12, Jennifer P Wisdom12, Joshua D Lee13.
Abstract
The EXIT-CJS (N = 1005) multisite open-label randomized controlled trial will compare retention and effectiveness of extended-release buprenorphine (XR-B) vs. extended-release naltrexone (XR-NTX) to treat opioid use disorder (OUD) among criminal justice system (CJS)-involved adults in six U.S. locales (New Jersey, New York City, Delaware, Oregon, Connecticut, and New Hampshire). With a pragmatic, noninferiority design, this study hypothesizes that XR-B (n = 335) will be noninferior to XR-NTX (n = 335) in retention-in-study-medication treatment (the primary outcome), self-reported opioid use, opioid-positive urine samples, opioid overdose events, and CJS recidivism. In addition, persons with OUD not eligible or interested in the RCT will be recruited into an enhanced treatment as usual arm (n = 335) to examine usual care outcomes in a quasi-experimental observational cohort.Entities:
Keywords: Buprenorphine; Criminal justice; Injection; Medication treatment; Naltrexone; Opioid use disorder
Mesh：
Substances：
Year: 2021 PMID： 33865691 PMCID： PMC8384640 DOI： 10.1016/j.jsat.2021.108389
Source DB: PubMed Journal: J Subst Abuse Treat ISSN： 0740-5472